Category Archives: Uncategorized

  • Novartis inks $2.1B Endocyte buyout

    Novartis has struck a $2.1 billion (€1.8 billion) deal to acquire Endocyte. The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 million just 12 months ago. Endocyte was in the doldrums when it pinned its hopes of recovery from previous clinical setbacks on radioligand […]...

  • 60th ASH Annual Meeting and Exposition

    National Search Associates is thrilled to have ASH in our hometown of San Diego CA this year. Events like ASH present a great opportunity for you to expand your network and potentially link up with other executives in your field. We are here to help. Having been in business for over 25 years, with a […]...

  • In Memoriam – Susan Weinstock

    Susan Weinstock: Forever in our hearts and always in the sunsets…   It is with great sadness that we announce publicly the passing of our beloved colleague, and senior recruiter, Susan Weinstock. Susan passed unexpectedly from complications with her cancer treatments earlier this year. It is, and remains, a tragic loss for her family, in...

  • Promotions & New Hires at National Search Associates

    Congratulations to Chelsea Brunetti & Eric Lona! They were recently promoted to Associate Director in January 2018. Both have placed a number of candidates in small and large biotech pharmaceutical companies for a number of years. They will continue representing our firm with excellence and new opportunities! https://www.linkedin.com/in/chelsea...

  • Johnson & Johnson’s Darzalex ambitions take a hit with scrapped I-O trials

    J&J partners with Genmab announced that they will stop studies of Darzalex in combination with anti-pd-l1, since it failed to show benefit. This prompted Janssen to discontinue phase 1b/2 study and phase 1 trial examining Darzalex alongside J&J PD-1 candidate in multiple myeloma patients. Read More of this article here....

  • Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn

    Novartis announced they will merge with AveXis Inc. for 218 per share or a total of 8.7 billion in cash, this transaction was unanimously approved by Boards of both companies. AveXis has ongoing clinical studies for the treatment of SMA, spinal muscular atrophy, this is the number one genetic cause of death in infants. This […]...

  • New, High-Impact Studies to Be Featured at World’s Largest Clinical Cancer Research Meeting

    The 2018 Annual Meeting will take place June 1-5 in Chicago and will bring more than 32,000 oncology professionals from around the world. The theme of this year’s conference is Delivering Discoveries Expanding the Reach of Precision Medicine. June is a very exciting time for the team here at National Search Associates. Every year a […]...

  • National Search Associates Successfully Recruits CEO for Legend Biotech: Yuan Xu

    Nathan Hipp, VP at National Search Associates, collaborated with Legend Biotech to help them identify and hire their first CEO, marking an important milestone for the newly minted CAR-T biotech. Yuan Xu was previously Sr. Vice President Biologics and Vaccines at Merck where she led Merck Biologics, Biosimilar, & Vaccines discovery, development,...

Get in touch

LinkedIn

View our profile